| Type 2 Diabetes Mellitus |
1 |
1 |
| Geriatrics |
0 |
0.99 |
| Hypoglycemia |
0 |
0.44 |
| Cardiovascular Risk Management |
0 |
0.34 |
| Heart Failure (HF) |
0 |
0.28 |
| Coronary Artery Disease (CAD) |
0 |
0.26 |
| Hypertension |
0 |
0.25 |
| Cardiometabolic Risk Factors |
0 |
0.23 |
| Adverse Effects |
0 |
0.22 |
| Cognitive Impairment |
0 |
0.21 |
| Cardiovascular disease |
0 |
0.18 |
| Impairment |
0 |
0.18 |
| Patient Safety |
0 |
0.17 |
| Exercise |
0 |
0.15 |
| Heart |
0 |
0.15 |
| Insulin Therapy |
0 |
0.15 |
| GLP-1 Receptor Agonist |
0 |
0.13 |
| Weight Management |
0 |
0.12 |
| Chronic Disease |
0 |
0.11 |
| Frailty |
0 |
0.11 |
| Sarcopenia |
0 |
0.11 |
| SGLT2 Inhibitor |
0 |
0.11 |
| Sulfonylureas |
0 |
0.11 |
| Weight Loss |
0 |
0.11 |
| Mild Cognitive Impairment |
0 |
0.09 |
| Muscular Atrophy |
0 |
0.09 |
| Renal Disease |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |
| Chronic Kidney Disease |
0 |
0.07 |
| Insurance |
0 |
0.07 |
| Nutrition |
0 |
0.07 |
| Receptors |
0 |
0.07 |